Literature DB >> 26074697

Loss of Dicer1 impairs hepatocyte survival and leads to chronic inflammation and progenitor cell activation.

Xu-Feng Lu1, Yong-Jie Zhou1, Lei Zhang1, Hong-Jie Ji1, Li Li1, Yu-Jun Shi1, Hong Bu1.   

Abstract

AIM: To investigate the continuous hepatic histopathological processes which occur in response to the loss of Dicer1.
METHODS: We generated a hepatocyte-selective Dicer1 knockout mouse and observed the gradual hepatic histopathological changes in the mutant liver. Immunohistochemistry and Western blotting were performed to detect Dicer1 expression. We performed hematoxylin and eosin staining, Periodic acid-Schiff staining, Oil Red O staining, and Masson's trichrome staining to detect histological changes in Dicer1-deficient livers. Ki67 immunohistochemistry, terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling assay, and Western blotting were used to determine hepatocyte proliferation and apoptosis. Serum biochemistry, cytokine assays, and flow cytometric analysis were performed to quantity liver necrosis and inflammation. Fibrogenic markers were determined by Western blotting and qPCR. CK19, CD133, and OV6 immunofluorescence were used to observe liver progenitor cells. Immunofluorescence and qPCR were performed to reveal embryonic gene expression. We also performed histological staining and Western blotting to analyze hepatocellular carcinoma (HCC) development.
RESULTS: Dicer1 inactivation resulted in significant architecture disorganization and metabolism disruption in the liver. Dicer1 disruption impaired hepatocyte survival and resulted in profound cell apoptosis and continuous necrosis. In contrast to previous reports, the mutant liver exhibited chronic inflammation and progressive fibrosis, and could not be repopulated by Dicer1-positive cells. In addition, extensive activation of hepatic progenitor cells was observed. Primary HCC was observed as early as 4 mo after birth.
CONCLUSION: Hepatic loss of Dicer1 results in complex chronic pathological processes, including hepatocyte death, inflammatory infiltration, chronic fibrosis, compensatory proliferation, progenitor activation, and spontaneous hepatocarcinogenesis.

Entities:  

Keywords:  Dicer1; Hepatocellular carcinoma; Liver fibrosis; Liver inflammation; microRNAs

Mesh:

Substances:

Year:  2015        PMID: 26074697      PMCID: PMC4458769          DOI: 10.3748/wjg.v21.i21.6591

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  39 in total

1.  miR-122 is more than a shield for the hepatitis C virus genome.

Authors:  Adolfo García-Sastre; Matthew J Evans
Journal:  Proc Natl Acad Sci U S A       Date:  2013-01-16       Impact factor: 11.205

2.  Adaptive immunity suppresses formation and progression of diethylnitrosamine-induced liver cancer.

Authors:  Carlo Schneider; Andreas Teufel; Tetyana Yevsa; Frank Staib; Anja Hohmeyer; Gudrun Walenda; Henning W Zimmermann; Mihael Vucur; Sebastian Huss; Nikolaus Gassler; Hermann E Wasmuth; Sergio A Lira; Lars Zender; Tom Luedde; Christian Trautwein; Frank Tacke
Journal:  Gut       Date:  2012-01-20       Impact factor: 23.059

Review 3.  MicroRNA signatures in human cancers.

Authors:  George A Calin; Carlo M Croce
Journal:  Nat Rev Cancer       Date:  2006-11       Impact factor: 60.716

4.  miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting.

Authors:  Christine Esau; Scott Davis; Susan F Murray; Xing Xian Yu; Sanjay K Pandey; Michael Pear; Lynnetta Watts; Sheri L Booten; Mark Graham; Robert McKay; Amuthakannan Subramaniam; Stephanie Propp; Bridget A Lollo; Susan Freier; C Frank Bennett; Sanjay Bhanot; Brett P Monia
Journal:  Cell Metab       Date:  2006-02       Impact factor: 27.287

5.  IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis.

Authors:  Shin Maeda; Hideaki Kamata; Jun-Li Luo; Hyam Leffert; Michael Karin
Journal:  Cell       Date:  2005-07-01       Impact factor: 41.582

Review 6.  MicroRNAs in liver disease.

Authors:  Gyongyi Szabo; Shashi Bala
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-05-21       Impact factor: 46.802

7.  Robust expansion of human hepatocytes in Fah-/-/Rag2-/-/Il2rg-/- mice.

Authors:  Hisaya Azuma; Nicole Paulk; Aarati Ranade; Craig Dorrell; Muhsen Al-Dhalimy; Ewa Ellis; Stephen Strom; Mark A Kay; Milton Finegold; Markus Grompe
Journal:  Nat Biotechnol       Date:  2007-07-29       Impact factor: 54.908

Review 8.  Oncomirs - microRNAs with a role in cancer.

Authors:  Aurora Esquela-Kerscher; Frank J Slack
Journal:  Nat Rev Cancer       Date:  2006-04       Impact factor: 60.716

Review 9.  Hepatocellular carcinoma biology.

Authors:  Boris Blechacz; Lopa Mishra
Journal:  Recent Results Cancer Res       Date:  2013

Review 10.  The role of microRNAs in liver cancer progression.

Authors:  S Huang; X He
Journal:  Br J Cancer       Date:  2010-11-23       Impact factor: 7.640

View more
  3 in total

1.  Genome-wide post-transcriptional regulation of bovine mammary gland response to Streptococcus uberis.

Authors:  Raana Tabashiri; Somayeh Sharifi; Abbas Pakdel; Mohammad Reza Bakhtiarizadeh; Mohammad Hossein Pakdel; Ahmad Tahmasebi; Colin Hercus
Journal:  J Appl Genet       Date:  2022-09-06       Impact factor: 2.653

Review 2.  RNAs and RNA-Binding Proteins in Immuno-Metabolic Homeostasis and Diseases.

Authors:  Esam S B Salem; Andrew D Vonberg; Vishnupriya J Borra; Rupinder K Gill; Takahisa Nakamura
Journal:  Front Cardiovasc Med       Date:  2019-08-20

3.  An individualized prognostic signature and multi‑omics distinction for early stage hepatocellular carcinoma patients with surgical resection.

Authors:  Lu Ao; Xuekun Song; Xiangyu Li; Mengsha Tong; You Guo; Jing Li; Hongdong Li; Hao Cai; Mengyao Li; Qingzhou Guan; Haidan Yan; Zheng Guo
Journal:  Oncotarget       Date:  2016-04-26
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.